Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis

WILMINGTON, Del.--(BUSINESS WIRE)--Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen and is under Priority Review for patients with asthma in the US. The...

Click to view original post